Skip to main content


Table 1 Clinical PARP inhibitors

From: Advances and perspectives of PARP inhibitors

PARP inhibitorOlaparibRucaparibNiraparibTalazoparibVeliparib
ApprovalsOvarian cancer
Breast cancer
Ovarian cancerOvarian cancerOvarian cancerNot approved
PARP trapping potencyMiddleMiddleMiddleHighLow
Recommended dose300 mg BID600 mg BID300 mg BID1 mg QD600 mg BID
The most common adverse reactions (in at least 20% patients)Anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitisNausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspneaNausea, thrombocytopenia, fatigue, anemia, constipation, vomiting, neutropenia, headache, decreased appetite, insomnia, abdominal painFatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetiteNausea, fatigue
  1. Data of Olaparib, Rucaparib, Niraparib, and Talazoparib are obtained from
  2. Data of Veliparib is obtained from NCT01149083